Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 55 Leukemia, Myeloid, Acute 38 Breast Neoplasms 38 Lymphoma, Large B-Cell, Diffuse 35 Multiple Myeloma 31 Lymphoma, Non-Hodgkin 29 Burkitt Lymphoma 29 Lymphoma 27 Myelodysplastic Syndromes 25 Triple Negative Breast Neoplasms 23 Recurrence 23 Hematologic Neoplasms 22 Lymphoma, B-Cell 21 Lymphoma, Follicular 20 Melanoma 16 Ovarian Neoplasms 15 Leukemia, Lymphocytic, Chronic, B-Cell 15 Neoplasm Metastasis 14 Leukemia 14 Hodgkin Disease 13 Neoplasms 12 Leukemia, Biphenotypic, Acute 12 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11 Pancreatic Neoplasms 11 Neuroblastoma 11 Leukemia, Myelomonocytic, Chronic 11 Lymphoma, Mantle-Cell 10 Graft vs Host Disease 10 Carcinoma, Non-Small-Cell Lung 10 Lymphoma, T-Cell, Peripheral 9

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Cancer Related Cognitive Decline × Cyclophosphamide × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡